Hallucinogens and Their Therapeutic Use: A Literature Review

Matthew J. Begola, Jason Schillerstrom

Research output: Contribution to journalArticle

Abstract

The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.

Original languageEnglish (US)
Pages (from-to)334-346
Number of pages13
JournalJournal of psychiatric practice
Volume25
Issue number5
DOIs
StatePublished - Sep 1 2019

Fingerprint

Hallucinogens
Therapeutic Uses
Psychiatry
Psilocybin
Banisteriopsis
Ibogaine
N-Methyl-3,4-methylenedioxyamphetamine
Lysergic Acid Diethylamide
Ketamine
Autistic Disorder
Sample Size
Substance-Related Disorders
Depression
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Hallucinogens and Their Therapeutic Use : A Literature Review. / Begola, Matthew J.; Schillerstrom, Jason.

In: Journal of psychiatric practice, Vol. 25, No. 5, 01.09.2019, p. 334-346.

Research output: Contribution to journalArticle

@article{76cdde902ab24b2d98310088d3442c07,
title = "Hallucinogens and Their Therapeutic Use: A Literature Review",
abstract = "The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.",
author = "Begola, {Matthew J.} and Jason Schillerstrom",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/PRA.0000000000000409",
language = "English (US)",
volume = "25",
pages = "334--346",
journal = "Journal of Psychiatric Practice",
issn = "1527-4160",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Hallucinogens and Their Therapeutic Use

T2 - A Literature Review

AU - Begola, Matthew J.

AU - Schillerstrom, Jason

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.

AB - The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.

UR - http://www.scopus.com/inward/record.url?scp=85072010561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072010561&partnerID=8YFLogxK

U2 - 10.1097/PRA.0000000000000409

DO - 10.1097/PRA.0000000000000409

M3 - Article

C2 - 31505518

AN - SCOPUS:85072010561

VL - 25

SP - 334

EP - 346

JO - Journal of Psychiatric Practice

JF - Journal of Psychiatric Practice

SN - 1527-4160

IS - 5

ER -